drugset / Trial / NCT07213349
Daridorexant for Alzheimer Disease Prevention
Phase 2
Recruiting
240 enrolled
Douglas Mental Health University Institute
Weston Family Foundation · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.
Timeline
- Start
- 2025-10-14
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daridorexant | Small molecule | 50 mg | Oral |